par Talamantes, Stephanie ;Lisjak, Michela ;Gilglioni, Eduardo Hideo ;Llamoza-Torres, Camilo;Ramos-Molina, Bruno;Gurzov, Esteban Nicolas
Référence JHEP Reports, page (100811)
Publication Publié, 2023-06-01
Référence JHEP Reports, page (100811)
Publication Publié, 2023-06-01
Article révisé par les pairs
Résumé : | Obesity-related complications such as non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D) are well-established risk factors for the development of hepatocellular carcinoma (HCC). This review provides insights into the molecular mechanisms that underlie the role of steatosis, hyperinsulinemia and hepatic inflammation in HCC development and progression. We focus on recent findings linking intracellular pathways and transcription factors that can trigger the reprogramming of hepatic cells. In addition, we highlight the role of enzymes in dysregulated metabolic activity and consequent dysfunctional signalling. Finally, we discuss the potential uses and challenges of novel therapeutic strategies to prevent and treat NAFLD/T2D-associated HCC. |